trending Market Intelligence /marketintelligence/en/news-insights/trending/yvvii471g6uumgj_p9yrsa2 content esgSubNav
In This List

Cardax adds 2 directors

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cardax adds 2 directors

Cardax Inc. appointed Makarand Jawadekar and Elona Kogan to its board.

Jawadekar, who has worked at Pfizer Inc. for 28 years, has experience in pharmaceutical research and development as well as knowledge of working in U.S., Europe, India and other parts of Asia, including Japan and China.

Kogan has been part of senior legal and operating positions at ARIAD Pharmaceuticals Inc. and Avanir Pharmaceuticals Inc.

Honolulu-based Cardax is a life sciences company focused on developing astaxanthin, an anti-inflammatory medicine.